PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7564164

A convenient conversion chart for obtaining serum LDL-cholesterol values.

N Ishihara
View original source ↗Export metadata ↓

Abstract

I devised a convenient conversion chart to obtain the LDL-cholesterol value from the measured total cholesterol, HDL-cholesterol and triglyceride values without calculations. The principles and the practical use of the chart are described. Its application to the development of slide calculators that allow direct reading of LDL-cholesterol value is also discussed.

Explore related subjects

Cholesterol, LDLData Interpretation, StatisticalHumansJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N Ishihara. 1995. A convenient conversion chart for obtaining serum LDL-cholesterol values.. https://doi.org/10.2739/kurumemedj.42.129

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Molecular biology of PCSK9: its role in LDL metabolism.

Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.

Cholesterol, LDL↗
PubMed2006

Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.

Statins are normally administered for the treatment of dyslipidemia on a daily basis. This standard dosing regimen is well tolerated by most patients. Occasionally, patients discontinue therapy secondary to side effects, most commonly myalgias. We describe 2 patients who were unable to tolerate daily atorvastatin therapy secondary to myalgias and were subsequently treated with rosuvastatin administered on Mondays, Wednesdays, and Fridays, with resolution of adverse effects. Significant reductions in serum low-density lipoprotein cholesterol levels were observed in the 2 patients despite the alternate-day dosing regimen. Rosuvastatin was chosen because of its long half-life (19 hours) and very high potency.

Cholesterol, LDL↗